tiprankstipranks
Trending News
More News >
ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
US Market
Advertisement

ArriVent BioPharma, Inc. (AVBP) Stock Forecast & Price Target

Compare
38 Followers
See the Price Targets and Ratings of:

AVBP Analyst Ratings

Strong Buy
9Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
Based on 9 analysts giving stock ratings to
ArriVent
BioPharma, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AVBP Stock 12 Month Forecast

Average Price Target

$39.38
▲(101.74% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for ArriVent BioPharma, Inc. in the last 3 months. The average price target is $39.38 with a high forecast of $45.00 and a low forecast of $32.00. The average price target represents a 101.74% change from the last price of $19.52.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","46":"$46","22.75":"$22.8","30.5":"$30.5","38.25":"$38.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$32.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,22.75,30.5,38.25,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.66,20.686153846153847,22.712307692307693,24.738461538461536,26.764615384615382,28.79076923076923,30.816923076923075,32.84307692307692,34.86923076923077,36.895384615384614,38.92153846153846,40.94769230769231,42.973846153846154,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.66,20.253846153846155,21.84769230769231,23.441538461538464,25.035384615384615,26.629230769230773,28.223076923076924,29.81692307692308,31.410769230769233,33.00461538461539,34.59846153846154,36.19230769230769,37.78615384615385,{"y":39.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.66,19.686153846153847,20.712307692307693,21.73846153846154,22.764615384615386,23.790769230769232,24.816923076923075,25.84307692307692,26.869230769230768,27.895384615384614,28.92153846153846,29.947692307692307,30.973846153846154,{"y":32,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.31,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.69,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.41,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.15,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.5,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.73,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.78,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.64,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.89,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$45.00Average Price Target$39.38Lowest Price Target$32.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading Analyst forecast on AVBP
JonesTrading
JonesTrading
$45
Buy
130.53%
Upside
Reiterated
08/15/25
ArriVent BioPharma, Inc.: Promising Future with Strong Financials and Key Data Releases Justifying Buy Rating
Citi
$40$33
Buy
69.06%
Upside
Reiterated
08/12/25
ArriVent Biopharma price target lowered to $33 from $40 at CitiArriVent Biopharma price target lowered to $33 from $40 at Citi
H.C. Wainwright Analyst forecast on AVBP
H.C. Wainwright
H.C. Wainwright
$40$42
Buy
115.16%
Upside
Reiterated
08/12/25
ArriVent Biopharma price target raised to $42 from $40 at H.C. WainwrightArriVent Biopharma price target raised to $42 from $40 at H.C. Wainwright
Guggenheim Analyst forecast on AVBP
Guggenheim
Guggenheim
$45
Buy
130.53%
Upside
Reiterated
08/11/25
Guggenheim Sticks to Their Buy Rating for ArriVent BioPharma, Inc. (AVBP)Maintaining our Buy rating and $45/shr PT.
LifeSci Capital Analyst forecast on AVBP
LifeSci Capital
LifeSci Capital
$38$37
Buy
89.55%
Upside
Reiterated
08/11/25
Positive Growth Trajectory and Buy Rating for ArriVent BioPharma, Inc. Driven by Promising Clinical Data and Strategic Development
B.Riley Financial Analyst forecast on AVBP
B.Riley Financial
B.Riley Financial
$37
Buy
89.55%
Upside
Reiterated
07/21/25
ArriVent BioPharma, Inc. (AVBP) Receives a Buy from B.Riley Financial
Goldman Sachs Analyst forecast on AVBP
Goldman Sachs
Goldman Sachs
Buy
Reiterated
07/18/25
We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.
Oppenheimer Analyst forecast on AVBP
Oppenheimer
Oppenheimer
$39$44
Buy
125.41%
Upside
Reiterated
06/24/25
ArriVent Biopharma price target raised to $44 from $39 at OppenheimerArriVent Biopharma price target raised to $44 from $39 at Oppenheimer
Clear Street Analyst forecast on AVBP
Clear Street
Clear Street
$32
Buy
63.93%
Upside
Initiated
06/24/25
ArriVent Biopharma initiated with a Buy at Clear StreetArriVent Biopharma initiated with a Buy at Clear Street
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading Analyst forecast on AVBP
JonesTrading
JonesTrading
$45
Buy
130.53%
Upside
Reiterated
08/15/25
ArriVent BioPharma, Inc.: Promising Future with Strong Financials and Key Data Releases Justifying Buy Rating
Citi
$40$33
Buy
69.06%
Upside
Reiterated
08/12/25
ArriVent Biopharma price target lowered to $33 from $40 at CitiArriVent Biopharma price target lowered to $33 from $40 at Citi
H.C. Wainwright Analyst forecast on AVBP
H.C. Wainwright
H.C. Wainwright
$40$42
Buy
115.16%
Upside
Reiterated
08/12/25
ArriVent Biopharma price target raised to $42 from $40 at H.C. WainwrightArriVent Biopharma price target raised to $42 from $40 at H.C. Wainwright
Guggenheim Analyst forecast on AVBP
Guggenheim
Guggenheim
$45
Buy
130.53%
Upside
Reiterated
08/11/25
Guggenheim Sticks to Their Buy Rating for ArriVent BioPharma, Inc. (AVBP)Maintaining our Buy rating and $45/shr PT.
LifeSci Capital Analyst forecast on AVBP
LifeSci Capital
LifeSci Capital
$38$37
Buy
89.55%
Upside
Reiterated
08/11/25
Positive Growth Trajectory and Buy Rating for ArriVent BioPharma, Inc. Driven by Promising Clinical Data and Strategic Development
B.Riley Financial Analyst forecast on AVBP
B.Riley Financial
B.Riley Financial
$37
Buy
89.55%
Upside
Reiterated
07/21/25
ArriVent BioPharma, Inc. (AVBP) Receives a Buy from B.Riley Financial
Goldman Sachs Analyst forecast on AVBP
Goldman Sachs
Goldman Sachs
Buy
Reiterated
07/18/25
We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.
Oppenheimer Analyst forecast on AVBP
Oppenheimer
Oppenheimer
$39$44
Buy
125.41%
Upside
Reiterated
06/24/25
ArriVent Biopharma price target raised to $44 from $39 at OppenheimerArriVent Biopharma price target raised to $44 from $39 at Oppenheimer
Clear Street Analyst forecast on AVBP
Clear Street
Clear Street
$32
Buy
63.93%
Upside
Initiated
06/24/25
ArriVent Biopharma initiated with a Buy at Clear StreetArriVent Biopharma initiated with a Buy at Clear Street
Stocks with the Highest Top Analyst Consensus in the General Sector
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ArriVent BioPharma, Inc.

1 Month
xxx
Success Rate
8/12 ratings generated profit
67%
Average Return
+2.07%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +2.07% per trade.
3 Months
xxx
Success Rate
7/12 ratings generated profit
58%
Average Return
+8.58%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +8.58% per trade.
1 Year
Robert BurnsH.C. Wainwright
Success Rate
5/12 ratings generated profit
42%
Average Return
-2.82%
reiterated a buy rating 25 days ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of -2.82% per trade.
2 Years
xxx
Success Rate
5/12 ratings generated profit
42%
Average Return
-5.24%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 41.67% of your transactions generating a profit, with an average return of -5.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AVBP Analyst Recommendation Trends

Rating
Mar 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
4
8
17
17
18
Buy
5
2
1
3
3
Hold
2
2
0
0
0
Sell
3
3
2
0
0
Strong Sell
0
0
0
0
0
total
14
15
20
20
21
In the current month, AVBP has received 21 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AVBP average Analyst price target in the past 3 months is 39.38.
Each month's total comprises the sum of three months' worth of ratings.

AVBP Financial Forecast

AVBP Earnings Forecast

Next quarter’s earnings estimate for AVBP is -$0.79 with a range of -$0.88 to -$0.66. The previous quarter’s EPS was -$0.90. AVBP beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.15% of the time in the same period. In the last calendar year AVBP has Outperformed its overall industry.
Next quarter’s earnings estimate for AVBP is -$0.79 with a range of -$0.88 to -$0.66. The previous quarter’s EPS was -$0.90. AVBP beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.15% of the time in the same period. In the last calendar year AVBP has Outperformed its overall industry.
No data currently available

AVBP Sales Forecast

Next quarter’s sales forecast for AVBP is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AVBP beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 53.02% of the time in the same period. In the last calendar year AVBP has Preformed in-line its overall industry.
Next quarter’s sales forecast for AVBP is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AVBP beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 53.02% of the time in the same period. In the last calendar year AVBP has Preformed in-line its overall industry.

AVBP Stock Forecast FAQ

What is AVBP’s average 12-month price target, according to analysts?
Based on analyst ratings, ArriVent BioPharma, Inc.’s 12-month average price target is 39.38.
    What is AVBP’s upside potential, based on the analysts’ average price target?
    ArriVent BioPharma, Inc. has 101.74% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AVBP a Buy, Sell or Hold?
          ArriVent BioPharma, Inc. has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
            What is ArriVent BioPharma, Inc.’s price target?
            The average price target for ArriVent BioPharma, Inc. is 39.38. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $45.00 ,the lowest forecast is $32.00. The average price target represents 101.74% Increase from the current price of $19.52.
              What do analysts say about ArriVent BioPharma, Inc.?
              ArriVent BioPharma, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of AVBP?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis